Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy

The autosomal recessive neuromuscular disease spinal muscular atrophy (SMA) is caused by loss of survival motor neuron (SMN) protein. Molecular pathways that are disrupted downstream of SMN therefore represent potentially attractive therapeutic targets for SMA. Here, we demonstrate that therapeutic targeting of ubiquitin pathways disrupted as a consequence of SMN depletion, by increasing levels of one key ubiquitination enzyme (ubiquitin-like modifier activating enzyme 1 [UBA1]), represents a viable approach for treating SMA. Loss of UBA1 was a conserved response across mouse and zebrafish models of SMA as well as in patient induced pluripotent stem cell–derive motor neurons. Restoration of UBA1 was sufficient to rescue motor axon pathology and restore motor performance in SMA zebrafish. Adeno-associated virus serotype 9–UBA1 (AAV9-UBA1) gene therapy delivered systemic increases in UBA1 protein levels that were well tolerated over a prolonged period in healthy control mice. Systemic restoration of UBA1 in SMA mice ameliorated weight loss, increased survival and motor performance, and improved neuromuscular and organ pathology. AAV9-UBA1 therapy was also sufficient to reverse the widespread molecular perturbations in ubiquitin homeostasis that occur during SMA. We conclude that UBA1 represents a safe and effective therapeutic target for the treatment of both neuromuscular and systemic aspects of SMA.

[1]  J. Melki,et al.  Spinal muscular atrophy. , 1997, Current opinion in neurology.

[2]  T. Gillingwater,et al.  Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian degeneration; Wlds) , 2008, Genome Biology.

[3]  M. Peschanski,et al.  Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes , 2014, Nature Biotechnology.

[4]  B. Wirth,et al.  SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. , 2010, Human molecular genetics.

[5]  K. Fischbeck,et al.  The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein , 2013, Molecular biology of the cell.

[6]  A. Joshi,et al.  Edinburgh Research Explorer Dysregulation of ubiquitin homeostasis and -catenin signaling promote spinal muscular atrophy , 2022 .

[7]  E. Hoffman,et al.  Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. , 2008, American journal of human genetics.

[8]  J. Sanes,et al.  Neuromuscular synapses can form in vivo by incorporation of initially aneural postsynaptic specializations , 2005, Development.

[9]  J. Moffat,et al.  The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. , 2010, Blood.

[10]  Liqun Luo,et al.  Axon Pruning during Drosophila Metamorphosis Evidence for Local Degeneration and Requirement of the Ubiquitin-Proteasome System , 2003, Neuron.

[11]  C. Henderson,et al.  Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. , 2011, The Journal of clinical investigation.

[12]  Jonathan D. Edwards,et al.  Abnormal motor phenotype in the SMNΔ7 mouse model of spinal muscular atrophy , 2007, Neurobiology of Disease.

[13]  Kevin A. Robertson,et al.  Differential Proteomics Analysis of Synaptic Proteins Identifies Potential Cellular Targets and Protein Mediators of Synaptic Neuroprotection Conferred by the Slow Wallerian Degeneration (Wlds) Gene*S , 2007, Molecular & Cellular Proteomics.

[14]  U. Monani,et al.  Molecular, Cellular and Developmental Biology Program – Specialization 2018/2019 , 2017 .

[15]  A. Ciechanover,et al.  Identification of a Region within the Ubiquitin-activating Enzyme Required for Nuclear Targeting and Phosphorylation* , 1997, The Journal of Biological Chemistry.

[16]  D. McCarty,et al.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis , 2001, Gene Therapy.

[17]  W. Hung,et al.  Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway , 2004, Neurochemistry International.

[18]  G. Hamilton,et al.  Spinal muscular atrophy: going beyond the motor neuron. , 2013, Trends in molecular medicine.

[19]  J. Melki,et al.  Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload. , 2004, The American journal of pathology.

[20]  Y. Jan,et al.  Dendrite-specific remodeling of Drosophila sensory neurons requires matrix metalloproteases, ubiquitin-proteasome, and ecdysone signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Fricker,et al.  Mouse model of spinal muscular atrophy. , 2000, Drug discovery today.

[22]  T. Jacques,et al.  Clinical and neuropathological features of X-linked spinal muscular atrophy (SMAX2) associated with a novel mutation in the UBA1 gene , 2013, Neuromuscular Disorders.

[23]  A. Verma.  Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN , 2011 .

[24]  D. Lamont,et al.  Label-free quantitative proteomic profiling identifies disruption of ubiquitin homeostasis as a key driver of Schwann cell defects in spinal muscular atrophy. , 2014, Journal of proteome research.

[25]  M. Ruitenberg,et al.  Adeno-associated viral vectors as agents for gene delivery: application in disorders and trauma of the central nervous system. , 2002, Methods.

[26]  Claire Heride,et al.  The demographics of the ubiquitin system. , 2015, Trends in cell biology.

[27]  Junmin Peng,et al.  Ubiquitin-specific Protease 9x Deubiquitinates and Stabilizes the Spinal Muscular Atrophy Protein-Survival Motor Neuron* , 2012, The Journal of Biological Chemistry.

[28]  B. Maria,et al.  Bone loss in survival motor neuron (Smn−/− SMN2) genetic mouse model of spinal muscular atrophy , 2009, The Journal of pathology.

[29]  K. Talbot,et al.  Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. , 2008, Human molecular genetics.

[30]  Y. Jong,et al.  Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[31]  Rachael A. Powis,et al.  Increased levels of UCHL1 are a compensatory response to disrupted ubiquitin homeostasis in spinal muscular atrophy and do not represent a viable therapeutic target , 2014, Neuropathology and applied neurobiology.

[32]  L. Tsai.  Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets , 2012, Neural plasticity.

[33]  Harold E. Smith,et al.  E1 Ubiquitin-Activating Enzyme UBA-1 Plays Multiple Roles throughout C. elegans Development , 2008, PLoS genetics.

[34]  C. Lorson,et al.  SMN-inducing compounds for the treatment of spinal muscular atrophy. , 2012, Future medicinal chemistry.

[35]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[36]  B. Mandefro,et al.  Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Have Reduced Expression of Proteins Important in Neuronal Development , 2016, Front. Cell. Neurosci..

[37]  A. Bergmann,et al.  The E1 ubiquitin-activating enzyme Uba1 in Drosophila controls apoptosis autonomously and tissue growth non-autonomously , 2007, Development.

[38]  C. Lorson,et al.  Decreasing disease severity in symptomatic, Smn(-/-);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery. , 2012, Human gene therapy.

[39]  M. Jędrzejowska,et al.  X-linked spinal muscular atrophy (SMAX2) caused by de novo c.1731C>T substitution in the UBA1 gene , 2015, Neuromuscular Disorders.

[40]  K. Fischbeck,et al.  Regulation of SMN Protein Stability , 2008, Molecular and Cellular Biology.

[41]  Y. Hua,et al.  Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. , 2010, Genes & development.

[42]  Ewout J. N. Groen,et al.  UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration , 2015, Trends in molecular medicine.

[43]  K. Fischbeck,et al.  Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. , 2011, Human molecular genetics.

[44]  C. Pfleger,et al.  Mutation in E1, the Ubiquitin Activating Enzyme, Reduces Drosophila Lifespan and Results in Motor Impairment , 2013, PloS one.

[45]  D. Meyerholz,et al.  Adaptive Immunity Does Not Strongly Suppress Spontaneous Tumors in a Sleeping Beauty Model of Cancer , 2013, The Journal of Immunology.

[46]  K. Fukuta,et al.  Morphological Study of the Transition of Haematopoietic Sites in the Developing Mouse During the Peri‐natal Period , 2006, Anatomia, histologia, embryologia.

[47]  J. Pearn,et al.  Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. , 1978, Journal of medical genetics.

[48]  A. Burghes,et al.  Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. , 2007, Neurobiology of disease.

[49]  B. Wirth,et al.  Moving towards treatments for spinal muscular atrophy: hopes and limits , 2015, Expert opinion on emerging drugs.

[50]  M. Rich,et al.  Temporal requirement for high SMN expression in SMA mice. , 2011, Human molecular genetics.

[51]  B. Wirth,et al.  Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. , 2011, Human molecular genetics.

[52]  U. Monani,et al.  Limited Phenotypic Effects of Selectively Augmenting the SMN Protein in the Neurons of a Mouse Model of Severe Spinal Muscular Atrophy , 2012, PloS one.